2021 Clinical Development Clinical Pharmacology 
Cytel
OCTOBER 27, 2023
Since its launch in 2021, Project Optimus has been reforming the dose optimization and dose selection paradigm in oncology drug development. Most of these post-approval changes have been overall decreases in dose. To address this challenge, the FDA Oncology Center of Excellence initiated Project Optimus.
The Premier Consulting Blog
JUNE 18, 2023
Figure 1: Comparison of Clinical Trial Designs The Prelude to Applying In Silico Trials for Rare Diseases In silico clinical trials have been recognized by the FDA as useful tools in advancing personalized treatment and streamlining randomized controlled trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
OCTOBER 1, 2021
The research, which spans clinical, health economics and outcomes research, translational, clinical pharmacology and preclinical presentations, highlights the breadth and depth of the company’s data on deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor, also because the emerging dermatology pipeline.
The Pharma Data
OCTOBER 15, 2020
Kozin will transition to the role of chairman in 2021, and Bennett Shapiro, the current chairman of the board, will step down from that role. OncoSec Medical – Sanda Aung was named chief clinical development officer for OncoSec Medical Incorporated. Shapiro will remain on the Board of Directors.
The Pharma Data
DECEMBER 17, 2020
In its Phase II clinical trial, TLC599 significantly reduced pain at and through every scheduled visit through six months. EXCELLENCE will evaluate the efficacy and safety of both a single and a repeated dose of TLC599; topline data of TLC’s leading program is expected in the second half of 2021.
Metabolite Tales Blog
JULY 5, 2023
With metabolic stability in mind, we take a look at the metabolism of some FDA approved synthetic macrocyclic drugs, and a few of those that were/are in clinical development where metabolism data was available. link] [9] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION. Gangl et al., Clin Cancer Res 27 (12): 3298–3306.
Metabolite Tales Blog
JULY 5, 2023
With metabolic stability in mind, we take a look at the metabolism of some FDA approved synthetic macrocyclic drugs, and a few of those that were/are in clinical development where metabolism data was available. link] [9] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION. Gangl et al., Clin Cancer Res 27 (12): 3298–3306.
Expert insights. Personalized for you.
64 
Let's personalize your content